News Library

Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
01/11/2017

Servier and GeNeuro Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017
28/10/2017

Servier establishes strategic research alliance with Harvard University
19/10/2017

Servier opts for Saclay as its future Research Centre
04/10/2017

Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T
29/06/2017

Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness
27/06/2017

Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
09/03/2017

Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
06/01/2017

New Compound shows promise in treating multiple human cancers
20/10/2016

Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
11/07/2016

Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have a New Treatment Option as LONSURF® (trifluridine/tipiracil) Receives EU Approval
27/04/2016

ISHR-ES – Servier Research Fellowship 2016 awarded to Dr Hector Cabrera-Fuentes
22/04/2016

40th year of operations in Brazil
06/04/2016

Servier Receives Positive CHMP Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
26/02/2016

Spectrum Pharmaceuticals Signs a Strategic Partnership with Servier Canada
11/01/2016

Servier announces expansion of collaboration for the development and commercialization of anticancer drug candidates targeting apoptosis
07/12/2015

Horizon Discovery Group plc In-licenses Oncology Programme from Servier and Enters Option Agreement
07/10/2015

Servier offers its expertise in industrial R&D, chemical synthesis and pharmaceutical manufacturing to partners.
05/10/2015

Cellectis Reaches Milestone in Servier Collaboration
09/07/2015

VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER
17/06/2015

Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
15/06/2015

FDA approves ivabradine for patients with chronic heart failure
16/04/2015

Servier, 8th European investor in the pharmaceutical sector
15/12/2014

GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of Multiple Sclerosis
02/12/2014

Intarcia and Servier sign ex-U.S. partnership for ITCA 650 in diabetes; Intarcia retains independence & full control of the U.S. & Japan
12/11/2014

Servier new research partnership with the Walter and Eliza Hall Institute to target Achilles’ heel of many cancers
02/10/2014

Servier and CTI Biopharma announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI®
17/09/2014

Xention and Servier commence first phase 2 study of XEN-D0103/S66913 in atrial fibrillation
01/09/2014

Servier Research Grant in Hypertension
27/08/2014

Galapagos receives milestone in osteoarthritis alliance with Servier
06/08/2014

Vernalis and Servier achieve two Research Milestones in their Oncology Collaborations
06/08/2014

Servier announces that its partner MacroGenics has initiated the first Phase 1 Study for MGD006/ S80880 for the Treatment of Acute Myeloid Leukemia
18/07/2014

Servier launches Cardiological, a mobile medical application to understand cardiovascular diseases
03/07/2014

Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs for Cardiovascular Disease
23/06/2014

Vernalis and Servier achieve Research Milestone as BCL-2 inhibitor drug candidate enters Phase I
19/06/2014

The winner of the 2014 Jean Delay Prize is Professor Mitsumoto Sato, from Japan
07/05/2014